Hagiwara, Shin-ichiro
Abe, Naoki
Hosoi, Kenji
Hara, Tomoko
Ishige, Takashi
Shimizu, Hirotaka
Mizuochi, Tatsuki
Kakiuchi, Toshihiko
Kunisaki, Reiko
Matsuoka, Ryo
Kondou, Hiroki
Kakuta, Fumihiko
Nakayama, Yoshiko
Kimura, Takeshi
Maeyama, Takatoshi
Honma, Hitoshi
Hirano, Daishi
Saruta, Masayuki
Yoshida, Tsutomu
Okayasu, Isao
Etani, Yuri
Funding for this research was provided by:
The Uehara Memorial Foundation Research Grant (2018-181)
Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics Grant (30-Y17)
Grant-in-Aid from the Japanese Society of Pediatric Inflammatory Bowel Disease (2019-4)
Article History
Received: 5 February 2023
Accepted: 16 June 2023
First Online: 19 June 2023
Competing interests
: Tatsuki Mizuochi reports personal fees from AbbVie GK and EA Pharma Co., Ltd. Masayuki Saruta reports personal fees from Abbvie GK, Janssen Pharma K.K., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd, Gilead Sciences K.K.; grant for commissioned/joint research from EPS Corporation: Scholarship grants from Zeria Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, EA Pharma Co., Ltd, Kissei Pharmaceutical Co., Ltd. Reiko Kunisaki reports research grant and speaker’s and/or consultancy fees from AbbVie GK, EA Pharma Co., Ltd, Eli Lilly, Janssen Pharmaceutical, JIMRO Co., Ltd., Kissei Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., outside the submitted work. Other authors declare that they have no conflict of interest.